DLL4 and neoplasm: Moreover, targeting DLL4 looked like as an appealing strategy as an anti-DLL4 antibody was efficacious against both WT and mutant KRAS in combination with irinotecan, decreasing the population of colon cancer stem cells and promoting apoptosis in tumor cells both in vitro and in xenograft models [222,537].